TORONTO, April 3, 2023 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ: GBNH) ("Greenbrook" or the "Company") today announced that the Company has amended its amended and restated master sales agreement ...
Please provide your email address to receive an email when new articles are posted on . The FDA has granted clearance to a transcranial magnetic stimulation device as an adjunctive treatment for major ...
Most people know depression can be treated with therapy and medication. Fewer realize that for the many patients whose depression doesn't respond to these standard approaches, there's an FDA-approved ...
While devices that stimulate the brain invasively have generally been available since 2002, and devices that do so non-invasively have been available since 2013, in recent years, the U.S. Food and ...
NeuroStar Advanced Therapy is a transcranial magnetic stimulation system that uses magnetic fields to induce neural activity in the cerebral cortex. The Food and Drug Administration (FDA) has cleared ...
NRx Pharmaceuticals (NRXP) amended its Investigational New Drug filing for NRX-101 to include the use of NRX-101 in association with Transcranial Magnetic Stimulation for the treatment of depression, ...
BrainsWay has achieved a successful turnaround with positive adjusted EBITDA and cash flow in Q3/23. The company offers advanced TMS therapy devices and has numerous patents. There are plenty of ...
The US Food and Drug Administration (FDA) granted 510K clearance to market a new transcranial magnetic stimulation (TMS) device, the MagVita TMS Therapy system from MagVenture, for treatment of adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results